Brent Hatzis-Schoch Esq., J.D.
Net Worth

Last updated:

What is Brent Hatzis-Schoch Esq., J.D. net worth?

The estimated net worth of Mr. Brent Hatzis-Schoch Esq., J.D. is at least $5,104,682 as of 12 May 2021. He owns shares worth $22,176 as insider, has earned $1,731,356 from insider trading and has received compensation worth at least $3,351,150 in Black Diamond Therapeutics, Inc..

What is the salary of Brent Hatzis-Schoch Esq., J.D.?

Mr. Brent Hatzis-Schoch Esq., J.D. salary is $670,230 per year as Chief Operating Officer & Gen. Counsel in Black Diamond Therapeutics, Inc..

How old is Brent Hatzis-Schoch Esq., J.D.?

Mr. Brent Hatzis-Schoch Esq., J.D. is 60 years old, born in 1965.

What stocks does Brent Hatzis-Schoch Esq., J.D. currently own?

As insider, Mr. Brent Hatzis-Schoch Esq., J.D. owns shares in one company:

Company Title Shares Price per share Total value
Black Diamond Therapeutics, Inc. (BDTX) Chief Operating Officer & Gen. Counsel 8,400 $2.64 $22,176

What does Black Diamond Therapeutics, Inc. do?

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

BDTX logo
BDTX
Black Diamond Therapeutics, Inc.
$2.64

Brent Hatzis-Schoch Esq., J.D. insider trading

Black Diamond Therapeutics, Inc.

Mr. Brent Hatzis-Schoch Esq., J.D. has made 12 insider trades between 2020-2021, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 179,915 units of BDTX stock on 12 Apr 2021. As of 12 May 2021 he still owns at least 8,400 units of BDTX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 4,078 $3.2 $13,050
Option
Stock Option (Right to Buy) 4,078 $3.2 $13,050
Sale
Common Stock 4,078 $27.4 $111,754
Sale
Common Stock 4,078 $27.4 $111,754
Sale
Common Stock 4,078 $25 $101,950
Option
Common Stock 4,078 $25 $101,950
Option
Stock Option (Right to Buy) 179,915 $3.2 $575,728
Option
Stock Option (Right to Buy) 4,078 $3.2 $13,050
Option
Common Stock 4,078 $3.2 $13,050
Sale
Common Stock 4,078 $3.2 $13,050
Sale
Common Stock 4,078 $27.43 $111,843
Sale
Common Stock 4,078 $27.43 $111,843
Option
Common Stock 4,078 $3.2 $13,050
Option
Stock Option (Right to Buy) 4,078 $3.2 $13,050
Option
Common Stock 11,578 $7.03 $81,393
Sale
Common Stock 11,578 $32.49 $376,204
Option
Stock Option (Right to Buy) 11,578 $7.03 $81,393
Option
Common Stock 11,578 $7.03 $81,393
Sale
Common Stock 11,578 $32.49 $376,204
Option
Stock Option (Right to Buy) 11,578 $7.03 $81,393
Option
Stock Option (Right to Buy) 5,400 $3.2 $17,280
Option
Common Stock 5,400 $3.2 $17,280
Sale
Common Stock 4,078 $3.2 $13,050
Option
Stock Option (Right to Buy) 4,078 $3.2 $13,050
Option
Common Stock 4,078 $3.2 $13,050
Option
Stock Option (Right to Buy) 4,078 $3.2 $13,050
Option
Common Stock 4,078 $3.2 $13,050
Sale
Common Stock 4,078 $34.24 $139,618
Option
Common Stock 4,078 $3.2 $13,050
Sale
Common Stock 4,078 $33.18 $135,320
Option
Stock Option (Right to Buy) 4,078 $3.2 $13,050
Option
Common Stock 4,078 $3.2 $13,050
Option
Stock Option (Right to Buy) 4,078 $3.2 $13,050
Sale
Common Stock 4,078 $31.58 $128,767
Purchase
Common Stock 3,000 $19 $57,000

Black Diamond Therapeutics key executives

Black Diamond Therapeutics, Inc. executives and other stock owners filed with the SEC: